Get the Stockscreener App
28.42
0.85%
0.1927
Collegium Pharmaceutical Inc stock is traded at $28.42, with a volume of 502.70K.
It is up +0.85% in the last 24 hours and down -21.09% over the past month.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
See More
Previous Close:
$28.23
Open:
$28.37
24h Volume:
502.70K
Relative Volume:
1.03
Market Cap:
$880.69M
Revenue:
$796.33M
Net Income/Loss:
$74.95M
P/E Ratio:
13.91
EPS:
2.0427
Net Cash Flow:
$329.83M
1W Performance:
+4.67%
1M Performance:
-21.09%
6M Performance:
-38.24%
1Y Performance:
-24.56%
1-Day Range:
$27.87
$29.01
1-Week Range:
$25.47
$29.30
52-Week Range:
$25.47
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
28.41 | 875.11M | 796.33M | 74.95M | 329.83M | 2.0427 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.52 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.59 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.44 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.39 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call - Yahoo Finance
Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock - Stock Titan
COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56 - webull.com
Can Collegium Pharmaceutical (NASDAQ:COLL) Rebound From Its Yearly Low? - Kalkine Media
Collegium Pharmaceutical Initiates $50 Million Accelerated Share Buyback with Jefferies LLC - Kalkine Media
Collegium Pharmaceutical stock jumps on $50M share buyback By Investing.com - Investing.com Canada
Why is Collegium Pharmaceutical stock climbing today? By Investing.com - Investing.com Canada
Collegium Pharmaceutical stock jumps on $50M share buyback - Investing.com
Collegium Pharmaceutical Launches $50 Million Accelerated Share Repurchase Program - citybiz
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com - Investing.com Nigeria
Collegium gains on $50M accelerated share buyback program - Seeking Alpha
Collegium Pharmaceutical to repurchase $50 million in stock - Investing.com
Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program - TradingView
Collegium Announces $50 Million Accelerated Share Repurchase Program - GlobeNewswire
Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year LowTime to Sell? - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Shares Down 6.5%Here's What Happened - MarketBeat
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance - Yahoo Finance
Collegium Pharmaceutical, Inc. Revenue Breakdown – NASDAQ:COLL - TradingView
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze - Sahm
Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Releases Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Cuts Target Price to $43 - Moomoo
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return - simplywall.st
Piper Sandler Reiterates Neutral Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Is Now The Time To Put Collegium Pharmaceutical (NASDAQ:COLL) On Your Watchlist? - Moomoo
Collegium Pharmaceutical, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-08-07 - Seeking Alpha
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unveiling an 82.76% Potential Upside - DirectorsTalk Interviews
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 1-Year Low Following Analyst Downgrade - MarketBeat
Collegium Pharmaceutical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Collegium Pharmaceutical stock hits 52-week low at 30.11 USD - Investing.com
Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside - TradingView
Needham & Company LLC Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $46.00 - MarketBeat
Collegium Pharmaceutical Releases Q2 2026 Financial Results - AlphaStreet
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap DownShould You Sell? - marketbeat.com
Collegium Pharmaceutical Down Over 13%, On Track for Largest Percent Decrease Since May 2024 -- Data Talk - Moomoo
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Collegium Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Collegium Pharmaceutical Q2 Earnings Call Highlights - MarketBeat
Collegium Pharmaceutical falls 13% on weak revenue guidance By Investing.com - Investing.com South Africa
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops - Yahoo Finance
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Collegium Pharmaceutical: Q2 Earnings Snapshot - marketscreener.com
Collegium Pharmaceutical Reports Q2 2026 Results, Completes AZSTARYS Acquisition and Raises Full-Year Guidance - Quiver Quantitative
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress - Yahoo Finance
Collegium Pharmaceutical, Inc. $COLL Shares Acquired by Sei Investments Co. - MarketBeat
Collegium Pharmaceutical (COLL): Principal Global Investors discloses 5% equity stake - Stock Titan
Collegium Pharmaceutical earnings ahead after ADHD acquisition By Investing.com - Investing.com Nigeria
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect - Barchart.com
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):